Objective: The atrial natriuretic peptide (ANP) is an important regulator of blood pressure 20 (BP). One of the mechanisms whereby ANP impacts BP is by stimulation of NO 21 production in different tissues involved in BP control. We hypothesized that ANP-22 stimulated NO is impaired in the kidneys of SHRs and this contributes to the development 23 and/or maintenance of high levels of blood pressure. We investigated the effects of ANP on 24 the NO system in SHR, studying the changes in renal NOS activity and expression in 25 response to peptide infusion, the signaling pathways implicated in the signaling cascade 26 that activates NOS and identifying the natriuretic peptide receptors (NPR), guanylyl cyclase 27 receptors (NPR-A and NPR-B) and/or NPR-C, and NOS isoforms involved. Results: Renal NOS activity was higher in SHR than in WKY. ANP increased NOS 35 activity, but activation was lower in SHR than in WKY. ANP had no effect on expression 36 of NOS isoforms. ANP-induced NOS activity was not modified by iNOS and nNOS 37 inhibitors. NPR-A/B blockade blunted NOS stimulation via ANP in kidney. Renal NOS 38 response to ANP was reduced by Gi protein and calmodulin inhibitors. 39
Introduction 46
Blood pressure is influenced by several vasoactive factors which also regulate renal 47
function. An imbalance in the regulation of salt and water reabsorption contributes to 48 hypertension. Two factors involved, nitric oxide (NO) and atrial natriuretic peptide (ANP), 49
are very important because of their hypotensive, diuretic and natriuretic effects 50 (15, 24, 25, 28) . Consequently, alterations in these two systems could be involved in the 51 development and/or maintenance of hypertension. 52 ANP exerts its biological actions through interaction with two specific membrane-bound 53 guanylyl cyclase receptors: natriuretic peptide receptor A (NPR-A) and B (NPR-B) (21, 27, 54 30) . A third natriuretic receptor subtype, NPR-C, has been proposed primarily as a 55 clearance receptor removing natriuretic peptides from the circulation, but now other 56 biological functions have also been reported (2, 4, 5) . In this regard, NPR-C is coupled to 57 adenylyl cyclase through an inhibitory guanine nucleotide regulatory protein (G i ) and/or to 58 activation of phospholipase C (PLC) (2, 30) . 59
On the other hand, the free radical nitric oxide (NO) is synthesized by a family of nitric 60 oxide synthases (NOS) that comprises neuronal (nNOS), inducible (iNOS) and endothelial 61 (eNOS) isoforms which are expressed in many tissues, including endothelium, vascular 62 smooth muscle, specific segments of the nephron, etc. (1,13). Both nNOS and eNOS are 63 expressed constitutively. The Ca 2+ -calmodulin complex is necessary to maintain the 64 enzyme active. In contrast, iNOS is expressed after transcriptional induction and it is 65 independent of intracellular Ca In previous studies we have demonstrated that ANP exerts its hypotensive, natriuretic and 69 diuretic effects, at least in part, through activation of cardiovascular and renal NOS (7, 9) . 70 Furthermore, we have reported that the NPR-C natriuretic receptor mediates activation of 71 NOS by ANP in the kidney (4,11). In contrast, McLay et al. have shown that, in cultures of 72 proximal tubular cells, ANP inhibits iNOS activity via NPR-C and cGMP (22) . 73
Additionally, we have also shown that ANP interacts with NPR-A and/or B natriuretic 74 receptors in the kidney, resulting in NOS activation (4, 11) . These results are in accordance 75 with studies performed in primary cultures of human proximal tubular cells which show 76 that NO synthesis can be stimulated by ANP via NPR-A receptors (23) . 77
The spontaneously hypertensive rats (SHR) is a genetic model of hypertension that shows 78 endothelial dysfunction, augmented oxidative stress, enhanced vasoconstrictor factors and 79 decreased bioavailability of NO (20, 29) . Moreover, high plasma levels of ANP and 80 increased NPR-A expression, associated with cGMP overproduction, have been observed in 81 this model of hypertension (19, 21, 24) . On the other hand, it has been shown that NO 82 synthesis could be enhanced in SHR, probably as a counter-regulatory mechanism activated 83 to compensate the increase in blood pressure (20, 33) . Several studies have found evidence 84 suggesting that the activity and/or expression of the different NOS isoforms in the kidney 85 are altered in this model, and that a differential expression of NOS isoforms is age-86 dependent (12, 17, 18, 20, 31, 33) . 87 We have recently found evidence that demonstrates that cardiovascular NOS response to 88
Protocol 1 115
Effects of ANP infusion on mean arterial pressure and the NO system 116 Rats were anaesthetized with urethane (1 g/kg bodyweight, i.p.; Sigma-Aldrich, St. Louis, 117
Missouri, USA) and the femoral vein and artery and the urinary bladder were cannulated 118 with a polyethylene catheter for drug administration (NaCl or ANP infusion), mean arterial 119 pressure (MAP) recording and urine collection, respectively. 120
The protocol is described in Figure 1a . After surgery, an infusion of isotonic sodium 121 chloride (NaCl 0.9 %) was started at a rate of 0.05 ml/min and maintained for 40 minutes to 122 allow stabilization of hemodynamic and renal parameters. The first 30 minutes following 123 stabilization were considered the control period, and the rate of isotonic NaCl infusion was 124 maintained at 0.05ml/min. At the end of this period, one group of SHR and WKY rats 125 received first a bolus of ANP (5 μg.kg respectively). The L-NAME dose used in this protocol induced no changes in MAP (36). 131
MAP was recorded at the end of the control and experimental periods. Urine samples were 132 collected during the control and experimental periods in all groups of animals. 133
Arterial blood pressure was measured with a Statham P23 ID pressure transducer (Gould 134 (Labtech Notebook, Laboratory Technologies Corporation, Wilmington, MA) . 137
Urine volume was determined gravimetrically and urinary sodium concentration was 138 evaluated with an ion analyzer (Tecnolab, . 139
The concentration of nitrites and nitrates (NOx), end products derived from NO metabolism, 140 in urine samples was determined according to the procedure described by Verdon et al. (34) . 141
At the end of the experimental period, animals were sacrificed by decapitation and kidneys 142 were removed in order to determine NOS activity and expression. 143
Determination of NOS activity 144
Tissue NOS activity was measured using [ by electrophoresis in 7.5% SDS-polyacrylamide gels, transferred to a nitrocellulose 160 membrane and then incubated with rabbit polyclonal anti-NOS antibodies (1/500 dilution: 161 anti-iNOS, anti-eNOS, anti-nNOS) or rabbit anti-phospho-eNOS Ser
1177
(1/500 dilution) 162 and a horseradish peroxidase-conjugated goat anti-rabbit secondary antibody (1/5000 163 dilution). Samples were revealed by chemiluminescence using the enhanced 164 chemiluminescence reagent for 2-4 min. Quantification of the bands was performed by 165 digital image analysis using a Hewlett-Packard scanner and Totallab analyzer software. All 166 antibodies and Western blot reagents were purchased from Santa Cruz Biotechnology 167 (Santa Cruz, CA, USA). 168
Protocol 2 170
ANP effects on NOS activity in isolated renal medulla and cortex. Signaling cascade 171 involved in the interaction between ANP and NOS in SHR. 172 SHR and WKY rats were sacrificed by decapitation and NOS activity was measured in the 173 renal cortex and medulla (inner and outer medulla without papilla) using [ 14 C] L-arginine 174 as substrate. Tissue slices (2-3 mm thick) were incubated for 30 minutes at 37 ºC as 175 described in Protocol 1, but agonists (15 minutes after incubation was started) and/or 176 antagonists (at the beginning of the 30-minute incubation period) were added during the 177 incubation period according to the protocol described in Figure 1b . 178
Concentration-dependent stimulation of NOS activity by ANP in all tissues studied had 179 been performed in previous studies (M. A. Costa, unpublished observation Figure 2 ). The drop in BP induced by ANP was similar in both 204 SHR and WKY, but L-NAME pre-treatment had a more marked impact in WKY than in 205 SHR. With respect to the magnitude of L-NAME inhibition on ANP-induced BP decrease, 206 figure 2 shows that L-NAME treatment reduced the hypotensive effect of ANP in WKY by 207 58% (from 19 mmHg to 11 mmHg) versus 33% (from 21 mmHg to 7 mmHg) in SHR. 208
Notwithstanding, after L-NAME treatment, 67% of the ANP hypotensive effect was still 209 present in SHR versus 42% in WKY. 210
The ANP-induced reduction in MAP was accompanied by a rise in diuresis, natriuresis and 211 NOx excretion; the increase in these parameters was also more marked in WKY than in 212 SHR, indicating a lower renal response to ANP in hypertensive than in normotensive 213 animals ( Figure 2 and Table 1 ). When rats were treated with L-NAME before ANP 214 infusion, the effect of the peptide on urine flow and sodium excretion diminished in both 215 the SHR and WKY groups. However, L-NAME had a greater effect on renal response to 216 ANP in WKY than in SHR ( Figure 2 ). As expected, L-NAME treatment reduced NOx 217 excretion in all experimental conditions. 218
We then verified whether the increase in NOx excretion was associated with the stimulation 219 of renal NOS. NOS activity in response to saline or ANP infusion is shown in Figure 3 . In 220 renal cortex and medulla, NOS activity was higher in SHR than in WKY. ANP infusion 221 enhanced this activity in both groups of animals. ANP-induced NOS stimulation was lower 222 in SHR than in WKY, suggesting an impaired response to ANP in this model of 223
hypertension. 224
The three isoforms of NOS, eNOS, iNOS and nNOS, were expressed in renal cortex and 225 medulla ( Figure 4 ). Greater protein levels of all isoforms were present in the kidney of SHR In vitro experiments showed that ANP increased renal NOS activity in both groups (Table 2 , 235 Figure 6 ). ANP-induced NOS activity was blunted when L-NAME was added previously, 236 verifying that activity measured was NOS-specific (M. A. Costa, unpublished observation). 237
Similar to in vivo experiments, ANP-induced renal NOS activation was lower in SHR than 238 in WKY (Table 2, Figure 6) . 239
In order to analyze the isoform involved in NOS activation via ANP in this model, the 240 experiments were performed in the presence of an inhibitor of iNOS (AG) or an inhibitor of 241 nNOS (7-NI). In all renal tissues, neither basal nor ANP-induced NOS activity was 242 modified by nNOS inhibition (Table 2, Figure 6 ) in either group, while iNOS blockade 243 provoked a decrease in basal NOS activity in both groups. This reduction was higher in 244 both renal cortex and medulla in SHR relative to WKY (Table 3 ). It is known that Ca-245 calmodulin is required for eNOS activity (1). Thus, our results showed that the inhibition of 246 this complex decreased basal NOS activity in both groups. Combined inhibition of Ca-247 calmodulin and iNOS blockade, abolished NOS activity in the tissues studied, indicating 248 that both isoforms are involved in basal NOS activity observed in kidney (Table 2, Figure13 6). The effect of iNOS blockade on NOS activity was similar in basal and in ANP-250 stimulated conditions in both tissues, indicating that the inducible isoform is not stimulated 251 by ANP (Table 3) . 252
The ANP-induced increase in NOS activity was abolished by calmidazolium in both SHR 253 and WKY renal cortex and medulla, implying a Ca diminished in SHR relative to WKY, and that there is a decrease in abundance of eNOS 296 protein in the inner medulla of SHR kidney (17, 18) . With regard to these findings, our 297 results have shown that the three isoforms of the enzyme are expressed in renal cortex and 298 medulla in both groups of animals. Accordingly, tissues from hypertensive rats showed 299 greater protein levels of the three isoforms than levels present in normotensive ones. These 300 results indicate that the up-regulation of NOS isoforms in renal tissues may play an 301 important role in the compensatory mechanism in response to elevation of systolic blood 302 pressure during the development of hypertension in SHR. Our data reinforce other author's 303 results demonstrating that development of hypertension is not due to a primary impairment 304 of NO production in SHR (33). 305
Nevertheless, we cannot disregard the possibility that the increment in oxidative stress 306 induced by the increase in peroxynitrites production may also be involved in maintenance 307 of the high levels of blood pressure in this model of hypertension (14,16). 308
Our in vivo studies showed that ANP treatment reduced MAP in both normotensive and 309 hypertensive animals. NOS blockade blunted the ANP hypotensive effect in both groups 310 but L-NAME treatment had a more marked impact in normotensive ones. These results 311 confirm our previous findings indicating that the NO system is involved in the hypotensive 312 effect induced by ANP, and this response is impaired in hypertensive animals (6,9). Thus, 313 our results suggest that ANP hypotensive effects involve different mechanisms in SHR and 314 in WKY, indicating that the NO system plays a more important role in ANP hypotensive 315 effect in WKY than in SHR. Moreover, increased NPR-A expression, associated with 316 cGMP overproduction, have been observed in this model of hypertension (19, 21, 24) .activation of particulate guanylyl cyclase-coupled NPR-A receptor, increasing cGMP 319 production through a mechanism that involves neither NO production nor soluble guanylyl 320 cyclase activity. 321
In the present study we have also shown that acute infusion with ANP increased NOS 322 activity in renal medulla and cortex in both groups. However, in agreement with our 323 previous results in normotensive animals, the increase in renal NOS activity would not be 324 L-NAME (1μM) or AG (1 mM) or 7-NI (10 μM) or Cz (1μM) or A (100 nM) or PTx (800 ng/ml) or KT-5823 (2 μM). 
